Why Is Accuray (NASDAQ:ARAY) Sliding 8.12% Before the Open on Tuesday?

Vinay Lochav

10 November 2026 11:44 PM AEDT

Why Is Accuray (NASDAQ:ARAY) Sliding 8.12% Before the Open on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Accuray (NASDAQ:ARAY) was indicated at USD 3.51 pre-market on November 10, 2026, lower by 8.12% against a calculated prior close of USD 3.82, a drop of around USD 0.31 per share.
Working from the row, USD 3.51 is 8.12% beneath USD 3.82, so a 100 share parcel lost roughly USD 31 in value before the opening bell.
A published summary of the latest Quarterly Report points to Revenue down 7% and a wider net loss, but the release date and exact figures could not be verified for this article.
Pre-market trading on Nasdaq runs from 4:00 a.m. to 9:30 a.m. ET, and a 5 cent move on a USD 3.51 quote equals 1.42%, so spreads matter.

What Drove Accuray Lower Before the Open (-8.12%)

The screener snapshot taken before the open on November 10, 2026 shows Accuray (NASDAQ:ARAY) at USD 3.51, down 8.12%. Back-calculating gives a Monday, November 9 close near USD 3.82 (3.51 divided by 0.9188), a gap of USD 0.31. The company makes radiation oncology equipment, and its stock sits in the lower half of a screener universe of 4,622 names. On a USD 3.82 base, each 1% equals about 3.8 cents, so the move spans roughly eight of those increments. Published coverage describes a recent report with revenue down 7% year over year and a widening net loss, and a separate headline refers to withdrawn outlook language. The dates could not be confirmed, so both should be treated as unverified context rather than the cause of today's decline.

The Reasoning: Catalyst Versus General Mechanisms

No catalyst has been identified in published coverage dated November 9 or November 10, 2026. That matters, since a move of 8.12% with no news is often just order imbalance in thin trading. As general background, pre-market falls in medical device names typically follow Earnings misses, lowered or withdrawn guidance, Equity or convertible raises, analyst downgrades, or read-across from a peer. A Capital equipment seller books revenue when systems are installed, so a delay on one large order can move a whole quarter. Orders and Backlog drive the forward view, and a thinner backlog can weigh on the multiple even if revenue holds. Debt matters too: heavy interest costs against a net loss leave little room for a revenue shortfall, and lenders can tighten terms.

Valuation, Liquidity and Risks

At USD 3.51 the stock trades well below the levels of earlier years, and investors should check the 52-week high and low on a live quote. Pre-market Volume is a fraction of the regular session, often under 5% of average daily volume, so a few hundred shares can print a gap. Spreads may be wide, perhaps 5 to 10 cents on a USD 3.51 quote. The main risks are a Reversal at the 9:30 a.m. ET open, further guidance changes, refinancing pressure, dilution from new share issuance and slow hospital capital budgets. An early decline does not predict the regular session, and a gap can close within minutes. Calculated figures here come from the screener row only and are not forecasts.

Where Things Stand

Accuray (NASDAQ:ARAY) is slipping 8.12% pre-market on Tuesday, November 10, 2026, most likely on order flow in thin trading, as no catalyst was identified in published coverage. The indicated USD 3.51 compares with a calculated USD 3.82 prior close. Earlier coverage of a 7% revenue decline and a wider net loss gives background but is unconfirmed as the trigger. The open at 9:30 a.m. ET will show whether the USD 0.31 gap holds. Keep an eye on turnover, bid-ask gaps and any filing released today.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.